Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry
| Autor: | Antoni Riera-Mestre, Anna Rocci, Manuel Monreal, Javier Trujillo-Santos, Roberto Quintavalla, Farès Moustafa, J.M. Suriñach, Carmine Siniscalchi, Luis Jara-Palomares, Behnood Bikdeli, Riete Investigators |
|---|---|
| Přispěvatelé: | Vanassche, T, Siniscalchi, C., Quintavalla, R., Rocci, A., Riera-Mestre, A., Trujillo-Santos, J., Surinach, J. M., Jara-Palomares, L., Bikdeli, B., Moustafa, F., Monreal, M., Tufano, A. |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
030204 cardiovascular system & hematology 0302 clinical medicine Recurrence Risk Factors Fatal bleeding 030212 general & internal medicine Registries RISK Mortality rate Death all-cause Hazard ratio Confounding Venous Thromboembolism ASSOCIATION Middle Aged Pulmonary embolism ISCHEMIC-STROKE Female Fatal pulmonary embolism Life Sciences & Biomedicine medicine.medical_specialty Statin medicine.drug_class PULMONARY-EMBOLISM EXTENDED TREATMENT Lower risk 03 medical and health sciences Medicine General & Internal Internal medicine General & Internal Medicine Internal Medicine medicine Humans In patient cardiovascular diseases Death all-causes RECURRENCE METAANALYSIS Aged Science & Technology business.industry Statins Anticoagulants medicine.disease PREVENTION ASPIRIN Venous thomboembolism Hydroxymethylglutaryl-CoA Reductase Inhibitors business Pulmonary Embolism Venous thromboembolism |
| Zdroj: | EUROPEAN JOURNAL OF INTERNAL MEDICINE r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname |
| ISSN: | 0953-6205 |
| Popis: | BACKGROUND: The clinical outcomes during the course of anticoagulation in patients with venous thromboembolism (VTE) using statins remain controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the risk for VTE recurrences, major bleeding or death during anticoagulation, according to the use of statins at baseline. We used propensity score-matching (PSM) to adjust for confounding variables. RESULTS: From February 2009 to January 2018, 32,062 VTE patients were included. Of these, 7,085 (22%) were using statins. Statin users were 10 years older (73±11 vs. 63±19 years, respectively) and more likely to have comorbidities or to be using antiplatelets or corticosteroids at baseline than non-users. During the course of anticoagulation (median, 177 days), 694 patients developed VTE recurrences, 848 bled and 3,169 died (fatal pulmonary embolism 176, fatal bleeding 121). Statin users had a similar rate of VTE recurrences (hazard ratio [HR]: 0.98; 95%CI: 0.82-1.17), a higher rate of major bleeding (HR: 1.29; 95%CI: 1.11-1.50) and a similar mortality rate (HR: 1.01; 95%CI: 0.93-1.10) than non-users. On PSM analysis, statin users had a significantly lower risk for death (HR: 0.62; 95%CI: 0.48-0.79) and a similar risk for VTE recurrences (HR: 0.98; 95%CI: 0.61-1.57) or major bleeding (HR: 0.85; 95%CI: 0.59-1.21) than non-users. CONCLUSIONS: During anticoagulation for VTE, patients using statins at baseline had a lower risk to die than non-users. ispartof: EUROPEAN JOURNAL OF INTERNAL MEDICINE vol:68 pages:30-35 ispartof: location:Netherlands status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect